🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Berodual® Respimat®

Found 10 matching trials

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

Study to compare the lung and oropharyngeal deposition of Berodual® (fenote...

Status

Terminated

Location

Multiple Locations

Start Date

2003-04

Trial ID

NCT02176200

Treatments Being Tested

Berodual® Respimat®, low inspiratory flow rate Berodual® Respimat®, medium inspiratory flow rate Berodual® Respimat®, high inspiratory flow rate Berodual® HFA-MDI, low inspiratory flow rate Berodual® HFA-MDI, medium inspiratory flow rate Berodual® HFA-MDI, high inspiratory flow rate

Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

N/A

Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose sol...

Status

Completed

Location

Multiple Locations

Start Date

2004-01

Trial ID

NCT02231359

Treatments Being Tested

Berodual® Respimat® solution for inhalation

Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

PHASE3

Study to demonstrate that at least one of the two doses of Berodual® (50 µg...

Status

Completed

Location

Multiple Locations

Start Date

1998-09

Trial ID

NCT02182505

Treatments Being Tested

Berodual® Respimat®, low dose Berodual® Respimat®, high dose Berodual® MDI

Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

PHASE3

Study to compare the effect of 'natural' as opposed to 'optimal' technique ...

Status

Terminated

Location

Multiple Locations

Start Date

2003-04

Trial ID

NCT02176187

Treatments Being Tested

Berodual® Respimat® inhaler Berodual® metered dose inhaler

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

PHASE3

The primary objective of this study was to investigate patients acceptabili...

Status

Completed

Location

Multiple Locations

Start Date

2002-10

Trial ID

NCT02173795

Treatments Being Tested

Berodual® Respimat®Berodual® MA HFA

Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

N/A

Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose sol...

Status

Completed

Location

Multiple Locations

Start Date

2004-03

Trial ID

NCT02231372

Treatments Being Tested

Berodual® Respimat® solution for inhalation

Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease

N/A

New perceptions about handling and patient satisfaction of the everyday use...

Status

Completed

Location

Multiple Locations

Start Date

2005-12

Trial ID

NCT02231320

Treatments Being Tested

Berodual® Respimat® - inhaler

Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease

N/A

New perceptions about handling and patient satisfaction of the everyday use...

Status

Completed

Location

Multiple Locations

Start Date

2005-10

Trial ID

NCT02231346

Treatments Being Tested

Berodual® Respimat® - inhaler

Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

To demonstrate that at least one of the two doses of Berodual® (50 µg fenot...

Status

Completed

Location

Multiple Locations

Start Date

1998-02

Trial ID

NCT02173782

Treatments Being Tested

Berodual® Respimat ® high dose Berodual® Respimat ® low dose Berodual® MDI Placebo

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

PHASE3

Study to demonstrate that at least one of the two doses of Berodual® (50 µg...

Status

Completed

Location

Multiple Locations

Start Date

1998-04

Trial ID

NCT02182479

Treatments Being Tested

Berodual® via Respimat®, high dose Berodual® via Respimat®, low dose Berodual® via MDI, high dose Placebo Respimat®Placebo MDI

Previous Next